Nipah virus envelope glycoprotein pseudotyped lentivirus
US11608509B2 · kind B2 · utility
5Cited by
3References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 20, 2017 |
| Grant date | Mar 21, 2023 |
| Priority date | — |
| Expiry date | Jun 2, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/18422
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.